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Abstract
Background Inconsistent results for coffee consumption and bladder cancer (BC) risk have been shown in epidemiological 
studies. This research aims to increase the understanding of the association between coffee consumption and BC risk by 
bringing together worldwide case–control studies on this topic.
Methods Data were collected from 13 case–control comprising of 5,911 cases and 16,172 controls. Pooled multivariate odds 
ratios (ORs), with corresponding 95% confidence intervals (CIs), were obtained using multilevel logistic regression models. 
Furthermore, linear dose–response relationships were examined using fractional polynomial models.
Results No association of BC risk was observed with coffee consumption among smokers. However, after adjustment for age, 
gender, and smoking, the risk was significantly increased for never smokers (ever vs. never coffee consumers:  ORmodel2 1.30, 
95% CI 1.06–1.59; heavy (> 4 cups/day) coffee consumers vs. never coffee consumers:  ORmodel2 1.52, 95% CI 1.18–1.97, p 
trend = 0.23). In addition, dose–response analyses, in both the overall population and among never smokers, also showed a 
significant increased BC risk for coffee consumption of more than four cups per day. Among smokers, a significant increased 
BC risk was shown only after consumption of more than six cups per day.
Conclusion This research suggests that positive associations between coffee consumption and BC among never smokers 
but not smokers.
Keywords Bladder cancer · Coffee consumption · Smoking · Dose–response analyses · Population-attributable risk
Abbreviations
BC  Bladder cancer
IARC  International Agency for Research on Cancer
BLEND  Bladder cancer epidemiology and nutritional 
determinants
FFQ  Food frequency questionnaires
OR  Odds ratio
CI  Confidence interval
POR  Pooled odds ratio
CYP1A2  Cytochrome P450 1A2
PAHs  Polycyclic aromatic hydrocarbons
ATM  Ataxia-telangiectasia mutated
PAR  Population-attributable risk
BMI  Body mass index
SES  Socioeconomic status
Introduction
Bladder cancer (BC) is the most common malignancy of 
the urinary tract and the seventh cause of death from cancer 
(2.8% of all cancer deaths), with nearly 430,000 new diag-
noses and 165,000 deaths per year worldwide [1, 2]. Three-
quarters of all BC cases occur in men [3], and most BC cases 
occur in the United States, Canada, and the European Union 
[4–7]. As with many solid tumors, BC incidence increases 
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with age and it rarely occurs before the age of 40–50 years 
[8]. Given that this cancer is easy to relapse, BC is reported 
to be the most expensive life-time treatment of all cancers 
raging from € 80,000 to € 160,000 per patient [9]. The 
strongest risk factors for BC occurrence, such as tobacco 
smoking and harmful chemicals [10], have long been identi-
fied. However, as the bladder is an excretory organ, the role 
of fluid consumption in the development of BC could also 
be important.
Coffee is one of the most consumed beverages in the 
world. Since early 1970s, the possible relationship between 
coffee consumption and BC has been of considerable inter-
est, when Cole et al. [11] suggested for the first time that 
coffee was a potential risk factor for BC. The International 
Agency for Research on Cancer (IARC) Monographs Pro-
gramme in 1991 stated that there was limited evidence on 
the effect of coffee consumption on the BC risk and subse-
quently classified coffee as “possibly carcinogenic” (group 
2B; Monographs Volume 51) [12]. Since then, several epide-
miological studies focused on the relationship between cof-
fee consumption and BC, however, results remained incon-
clusive [13–27]. In May 2016, a subsequent IARC Working 
Group of 23 scientists from 10 countries met to evaluate 
the carcinogenicity of drinking coffee and concluded that: 
“no consistent evidence of an association with drinking cof-
fee, or of an exposure–response gradient”. This conclusion 
was based on evidence from 10 cohort studies and several 
population-based case–control studies conducted in Europe, 
the United States, and Japan [28]. An explanation for this 
inconsistency may be that previous studies on the relation 
between coffee consumption and BC risk lacked sufficient 
sample size to identify a significant association. In addi-
tion, since heavy coffee consumption is shown to be strongly 
associated with tobacco smoking [29], positive associations 
reported in some studies could possibly have been due to 
inadequate control for tobacco smoking. Moreover, several 
studies showed smoking to be interactive with caffeine in 
coffee [30–35], and, thereby, lead to misleading results in 
un-stratified analysis on the relation between coffee con-
sumption and BC risk.
The present study aims to update the understanding and 
find more conclusive answers on the influence of coffee 
consumption on the BC risk by bringing together available 
case–control studies on the topic including almost 6,000 BC 
cases.
Methods
Study population
Data were derived from the BLadder cancer Epidemiology 
and Nutritional Determinants study (BLEND). BLEND is a 
large international epidemiology consortium aimed to pool 
data from available epidemiological studies on diet and BC. 
For the present study, 13 case–control studies (including 
5,911 cases/16,172 controls), originated from nine different 
countries in three continents (i.e., Europe, North America, 
and Asia) had sufficient information on coffee consumption 
to be eligible for inclusion. BC cases were diagnosed and 
histologically confirmed through each study center of the 
included individual studies, with International Classification 
of Diseases (ICD) nine or ten. Most of the BC cases were 
identified in 1990s.
Data collection and coding
Details on the methodology of the BLEND consortium have 
been described elsewhere [36]. Taking into account the local 
context of the included studies, different dietary assess-
ment methods were adopted: (1) self-administrated food 
frequency questionnaire (FFQ) were used in Germany-1 
[37], USA-2 [38], Canada-1 [39], France-1 [40], USA-3 
[41], USA-4 [42]; (2) FFQ administered by a trained inter-
viewer were used in USA-1 [43], Belgium-1 [44], China-1 
[45], Sweden-1 [46], Spain-1 [47], Italy-1 [48], Italy-2 [49]. 
Coffee consumption was categorized using the hierarchal 
Eurocode 2 food coding system developed by the European 
Union [50]. To obtain unified consumption across studies, 
weekly, monthly, or yearly coffee cups were converted to 
daily cups of coffee consumption.
In addition to information on coffee and other dietary 
intake data, the BLEND dataset also included data on: study 
characteristics (design, method of dietary assessment, recall 
time of dietary consumption, and geographical region), par-
ticipant demographics (age and gender), smoking status, and 
smoking pack-years.
Statistical analyses
To assess the influence of coffee consumption on the BC 
risk, multilevel logistic regression analyses were used to 
estimate the pooled odds ratios (ORs) and 95% confidence 
intervals (CIs). Coffee consumption was expressed as: (1) 
ever (individuals who drank coffee > 0 cup/day) or never 
consumption; (2) based on the available data, coffee con-
sumption was divided into six categories: never, 0–1 cup/
day, 1–2 cups/day, 2–3 cups/day, 3–4 cups/day, and more 
than four cups/day; (3) caffeinated or decaffeinated coffee 
consumption. In addition, standardized analysis on coffee 
cup size was performed. For this we transformed a United 
States (U.S.) cup size to a 237 ml coffee cup size according 
to U.S. Food and Drug Administration [51] and an Asian cup 
size to a 500 ml cup size according to the questionnaire used 
in the study of Lu et al. [45].
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The logistic regression models used never coffee con-
sumers as the reference group and were computed as 
“crude model” (model 1), adjusted for age, gender, smok-
ing (model 2), or fully adjustment (model 3) additionally 
adjusted other fluid consumption (i.e., water, liquid milk, 
tea, alcohol, carbonated drink, and juice). Smoking was 
defined as: 0 (never smokers); 1 [current light smokers 
(i.e., smoking less than 20 pack-years)]; 2 (current heavy 
smokers (i.e., smoking more than 20 pack-years)); 3 (for-
mer light smokers (i.e., smokers who ceased smoking over 
1 year and smoked less than 20 pack-years)]; 4 [former 
heavy smokers [i.e., smokers who ceased smoking over 
1 year and smoked more than 20 pack-years)]. In addition, 
the effect of ever versus never coffee consumption was also 
assessed using a meta-analysis approach; for this, pooled 
ORs (PORs) and 95% CIs were calculated by using a ran-
dom-effect model stratified by geographical regions (i.e., 
Europe, North America and Asia) and study designs (i.e., 
hospital-based case–control studies and population-based 
case–control studies). Due to the lack of data, the influence 
of caffeine on BC risk was only assessed by comparing 
ever (caffeinated vs. decaffeinated) versus never coffee 
consumers based on multilevel logistic regression (model 
2). To understand the relevance of the effect modifica-
tion, the interaction terms between coffee consumption and 
age, gender, smoking status with pack-years were added to 
the model 2. P interaction < 0.10 was considered statisti-
cally significant where upon analyses were stratified for 
the covariate of interest to understand the relevance of the 
effect modification.
In our secondary analysis, a potential dose–response 
relationship between coffee consumption and BC was 
assessed by using fractional polynomial regression, in 
which the best fitting second order fractional polynomial 
regression model was defined as the model with the low-
est deviance [52, 53]. A likelihood ratio test was used to 
assess the difference between the nonlinear and linear 
models to test for nonlinearity [54]. The results of the 
dose–response analyses were presented for each one coffee 
cup/day increment up to ten cups/day with stratification by 
smoking status (i.e., ever smokers and never smokers) and 
(i.e., hospital-based case–control studies and population-
based case–control studies). Adjustments (model 2) were 
made for age, gender, and smoking (in overall population).
Finally, the population-attributable risk (PAR) of heavy 
coffee consumption (i.e., > 4 cups/day) on BC risk was 
estimated for Europe and North America, using the pooled 
risk estimates and the proportion of BC incidence in the 
population of interest.
All statistical analyses were performed with STATA 
version 14 SE (Stata Corporation, Texas, USA). P values 
below 0.05 were considered statistically significant.
Results
Baseline characteristics
The baseline characteristics of the study population are 
shown in Table 1. Of more than 22,000 participants, 5,911 
cases of BC (4,639 men, 1,272 women) were identified. 
The median age at baseline was 61.4 years for cases and 
57.2 years for controls, respectively. Approximately 35% of 
participants reported drinking coffee more than four cups 
per day, with an average consumption of four cups/day over-
all. At baseline, a higher coffee consumption was observed 
among smokers (five cups/day) compared to never smokers 
(three cups/day). In addition, coffee consumption showed 
strong interaction with smoking status as well as pack-
years (p interaction: 0.001 and 0.042, respectively), while 
not interaction was found with age (p interaction: 0.17) and 
gender (p interaction: 0.16).
Associations between coffee consumption and BC 
risk
Ever versus never coffee consumption
The results comparing ever versus never coffee consumers 
are shown in Table 2 and Fig. 1. Overall, after adjustment 
for possible confounders, no statistically significant differ-
ence in BC risk could be observed between coffee consum-
ers versus never coffee consumers  (ORmodel2 1.11, 95% CI 
0.98–1.26;  ORmodel3 1.09, 95% CI 0.94–1.25). Among never 
smokers, a statistically significant association between cof-
fee consumption and the risk of BC was found after further 
adjustment  (ORmodel2 1.30, 95% CI 1.06–1.59;  ORmodel3 
1.31, 95% CI 1.03–1.66). For smokers, no significant asso-
ciation was observed comparing ever versus never coffee 
consumers. However, the estimates for former light smok-
ers showed to be slightly higher than the estimates for other 
smokers. In addition, the meta-analysis stratified by geo-
graphical regions presented similar PORs based on model 2 
 (POROverall 1.11, 95% CI 0.96–1.25;  POREurope 1.13, 95% CI 
0.88–1.37;  PORNorth America 1.11, 95% CI 0.88–1.34); with 
low heterogeneity (I2 = 0.0%; p = 0.57).
Categories of coffee consumption with BC risk
The results of multilevel logistic regressions for subsequent 
categories of coffee consumption are shown in Table 2. 
Overall, coffee consumption of more than four cups/day 
results in an increased BC risk of 1.27 (95% CI 1.11–1.46, p 
trend = 0.05, model 2) compared to never coffee consumers. 
A similar increased risk was observed among never smokers 
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when comparing high (> 4 cups/day) coffee consumption to 
never coffee consumers  (ORmodel2 1.52, 95% CI 1.19–1.94, 
p trend = 0.23). Among smokers no significant association 
could be observed; however, former light smokers showed 
again slightly higher and borderline significant results 
compared to other type of smokers  (ORmodel2 1.41, 95% CI 
0.99–2.02, p trend = 0.06). The coffee cup size standard-
ized analysis also showed significantly increased BC risk 
estimates with more than four cups/day coffee consumption 
(Supplementary Table 3).
Results for the comparison of caffeinated and decaffein-
ated coffee are shown in Supplementary Tables 1 and 2. 
For the analysis on caffeinated coffee consumption, only 1 
(France-1) out of the 13 included case–control studies could 
be included (including 187 cases/296 controls). For the anal-
ysis on decaffeinated coffee, two studies (Italy-1 and USA-4) 
Table 2  Adjusted odds ratios and 95% confidence intervals of bladder cancer according to coffee consumption level stratified by smoking
Referent group was never coffee consumers
OR odds ratio, CI confidence interval
a Model 1: Crude model
b Model 2: Adjusted for age, gender and smoking (in the overall analyses)
c Model 3: Additionally adjusted for water, liquid milk, alcohol, carbonated drinks, tea and juice
p trend < 0.05 were considered statistically significant
Study sub-
groups
Model adjust-
ments
Coffee consumption (ORs and 95% CI) p trend
Never Ever ≤ 1 cups/day 1–2 cups/day 2–3 cups/day 3–4 cups/day > 4 cups/day
Overall 
(n = 22,083)
Model  1a Reference 1.42 (1.26–
1.59)
1.05 (0.91–
1.22)
1.35 (1.17–
1.55)
1.23 (1.06–
1.42)
1.51 (1.31–
1.76)
1.82 (1.60–
2.07)
0.04
Model  2b Reference 1.11 (0.98–
1.26)
0.94 (0.80–
1.10)
1.12 (0.96–
1.29)
1.01 (0.86–
1.17)
1.16 (0.99–
1.35)
1.27 (1.11–
1.46)
0.05
Model  3c Reference 1.09 (0.94–
1.25)
0.92 (0.77–
1.10)
1.04 (0.88–
1.24)
0.97 (0.81–
1.15)
1.15 (0.96–
1.37)
1.24 (1.06–
1.45)
0.11
Current light 
smokers 
(n = 3,548)
Model  1a Reference 1.01 (0.68–
1.47)
0.75 (0.43–
1.30)
0.99 (0.64–
1.53)
0.71 (0.42–
1.19)
1.31 (0.84–
2.04)
1.09 (0.72–
1.63)
0.34
Model  2b Reference 0.97 (0.65–
1.43)
0.63 (0.36–
1.11)
0.92 (0.59–
1.44)
0.71 (0.42––
1.21)
1.24 (0.79–
1.94)
1.09 (0.72–
1.66)
0.23
Model  3c Reference 1.16 (0.71–
1.90)
0.71 (0.37–
1.35)
1.09 (0.63–
1.88)
0.80 (0.43–
1.49)
1.46 (0.85–
2.48)
1.25 (0.78–
2.07)
0.14
Current heavy 
smokers 
(n = 3,458)
Model  1a Reference 1.01 (0.71–
1.41)
0.91 (0.60–
1.39)
1.08 (0.74–
1.60)
0.92 (0.63–
1.35)
0.97 (0.65–
1.44)
1.06 (0.74–
1.51)
0.66
Model  2b Reference 1.01 (0.71–
1.42)
0.83 (0.54–
1.28)
0.99 (0.67–
1.47)
0.91 (0.62–
1.35)
0.97 (0.65–
1.46)
1.15 (0.80–
1.66)
0.57
Model  3c Reference 0.92 (0.59–
1.41)
0.75 (0.45–
1.24)
0.78 (0.48–
1.29)
0.82 (0.51–
1.32)
0.89 (0.55–
1.45)
1.03 (0.66–
1.61)
0.34
Former light 
smokers 
(n = 3,314)
Model  1a Reference 1.24 (0.91–
1.70)
1.03 (0.71–
1.51)
1.20 (0.82–
1.76)
1.36 (0.95–
1.97)
1.37 (0.90–
2.08)
1.29 (0.91–
1.83)
0.07
Model  2b Reference 1.28 (0.93–
1.75)
1.01 (0.68–
1.48)
1.19 (0.81–
1.75)
1.44 (0.99–
2.09)
1.36 (0.89–
2.08)
1.41 (0.99–
2.02)
0.06
Model  3c Reference 1.30 (0.90–
1.88)
1.05 (0.68–
1.62)
1.14 (0.74–
1.77)
1.50 (0.99–
2.27)
1.39 (0.87–
2.21)
1.38 (0.93–
2.07)
0.09
Former heavy 
smokers 
(n = 3,202)
Model  1a Reference 1.02 (0.76–
1.37)
0.83 (0.58–
1.17)
0.96 (0.67–
1.37)
0.90 (0.64–
1.26)
1.03 (0.71–
1.49)
1.28 (0.93–
1.76)
0.19
Model  2b Reference 1.01 (0.75–
1.35)
0.80 (0.57–
1.13)
0.93 (0.65–
1.33)
0.89 (0.63–
1.24)
1.03 (0.71–
1.49)
1.28 (0.93–
1.76)
0.18
Model  3c Reference 0.92 (0.66–
1.27)
0.72 (0.49–
1.05)
0.79 (0.53–
1.18)
0.78 (0.54–
1.13)
0.96 (0.64–
1.44)
1.20 (0.85–
1.70)
0.07
Never 
smokers 
(n = 7,289)
Model  1a Reference 1.36 (1.12–
1.67)
1.31 (1.01–
1.70)
1.53 (1.20–
1.96)
1.04 (0.78–
1.39)
1.31 (0.99–
1.74)
1.52 (1.19–
1.94)
0.23
Model  2b Reference 1.30 (1.06–
1.59)
1.18 (0.90–
1.55)
1.36 (1.05–
1.76)
0.96 (0.71–
1.30)
1.22 (0.91–
1.64)
1.52 (1.18–
1.97)
0.23
Model  3c Reference 1.31 (1.03–
1.66)
1.28 (0.95–
1.73)
1.42 (1.06–
1.89)
0.97 (0.70–
1.34)
1.24 (0.91–
1.70)
1.51 (1.15–
1.99)
0.24
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had sufficient data to be included in our analyses (including 
1,048 cases/1,487 controls). Consumers of caffeinated coffee 
showed significant increased risks (compared to decaffein-
ated coffee consumers:  ORmodel2 1.88, 95% CI 1.42–2.48; 
compared to never coffee consumers:  ORmodel2 1.52, 95% 
CI 1.06–2.21), whereas, decaffeinated coffee consumers 
showed a null association with BC compared to never cof-
fee consumers.
Dose–response analyses
Dose–response relationships between coffee consumption 
and the risk of BC are displayed in Fig. 2. The tests for 
nonlinearity were not statistically significant; hence, linear 
models were applied in the dose–response analyses. The 
curves for the overall population showed a slightly increased 
BC risks with the increment of coffee consumption. Similar 
results were found among ever and never smokers; however, 
among never smokers the increased BC risk was significant 
for consuming over four cups/day, while for ever smokers for 
consumption over six cups/day. Adjusted ORs and 95% CIs 
for one cup/day increment were 1.14 (95% CI 1.05–1.24) in 
overall study population, 1.05 (95% CI 1.02–1.15) in ever 
smokers, 1.16 (95% CI 1.04–1.41) in never smokers. In addi-
tion, both curves for hospital-based studies and population-
based studies showed increased BC risks with the increment 
of cups of coffee consumption per day. However, in hospi-
tal-based studies a statistically significant increase BC risk 
was observed for consuming over two cups/day, while for 
population-based studies a significant increase was observed 
for consuming over five cups/day (Supplementary Fig. 2).
Population‑attributable risks
Assuming an incidence of heavy coffee drinking of 28% 
and 17%, in Europe and North America respectively, a PAR 
of 7.94% for Europe and 4.45% for North America was 
observed.
Discussion
This large multi centric study found an overall increased risk 
of BC with high (> 4 cups/day) coffee consumption. In addi-
tion, we showed that this increased risk was only observed 
among never smokers, but not found among smokers.
The interaction between coffee and smoking has already 
been studied with some detail, and experimental studies 
showed that smokers eliminate caffeine faster, suggesting 
that the effect of coffee consumption on BC risk is lower 
among smokers [33, 55]. In fact, faster metabolism of caf-
feine in smokers would allow them to consume higher levels 
before experiencing symptoms of caffeine toxicity [56–58]. 
Moreover, this hypothesis is strengthened by experimental 
studies reporting that the cytochrome P450 1A2 (CYP1A2) 
metabolic pathway is upregulated by both caffeine and 
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Fig. 1  Forest Plot of Meta-Analysis with ORs and 95% CIs for Ever 
and Never Coffee Consumption with Bladder Cancer Risk Adjusted 
for Age, Gender and Smoking by Geographical Regions. OR odds 
ratio, CI confidence interval. Circle dots denote the odds ratios 
(ORs); Horizontal lines represent the 95% confidence intervals (CIs); 
Weights are from random-effect model. Europe pooled OR of studies 
from Europe; North America pooled OR of studies from North Amer-
ica; Overall pooled OR of all studies
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compounds in tobacco smoke, including nicotine and poly-
cyclic aromatic hydrocarbons (PAHs) [59–61], so that the 
effect of caffeine is potentially weaker among smokers than 
among never smokers. These experimental studies are in 
line with our result showing an increased BC risk among 
never smokers only. Several epidemiological studies (both 
case–control and cohort) also suggested a higher BC risks 
for coffee consumers among never smokers only or a null 
association among smokers [40, 62–66]. A meta-analysis of 
epidemiological studies also suggested that the increased BC 
risk of coffee consumption was higher among never smokers 
than among smokers [31]. However, a more recent prospec-
tive cohort study (2017) [67] conducted in the United States, 
which showed that high coffee consumption (> 4 cups/day) 
was positively associated with BC risk, could not observe 
an increased BC risk among never smokers only. This dis-
crepancy may be due to the limited number of cases in their 
smoking-stratified analysis.
Coffee contains high content of caffeine, which has shown 
mutagenic effects in human cells [68], a proven influence on 
suppressing the activation of the protein kinase ataxia-tel-
angiectasia mutated (ATM) and the phosphorylation of the 
kinase Chk2, both important for the activation of the tumor 
suppressor gene P53 [69, 70]. It could, therefore, be sug-
gested that the increased BC risk is due to the caffeine con-
tent of coffee. Previous epidemiological studies already con-
firmed this hypothesis by showing a null association between 
BC risk and decaffeinated coffee [71] and an increased BC 
risk for caffeinated coffee [72, 73]. The present study also 
showed an increased BC risk when comparing caffeinated 
coffee consumers versus decaffeinated coffee consumers. 
However, due to lack of data, we were unable to perform 
further analyses, i.e., the association between the intensity 
of caffeinated coffee consumption and BC.
Besides caffeine, coffee also included other compounds, 
such as several phenolic compounds (i.e., chlorogenic, 
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Fig. 2  Dose-response Relationships between Coffee Consumption 
and the Risk of Bladder Cancer among I) Overall study population; 
II) Ever Smokers; III) Never Smokers. The solid lines represent the 
odds ratios (ORs). The dashed lines represent the 95% confidence 
intervals (CIs) for the trend. The ORs were adjusted for age, gender 
and smoking (in the overall study population) (model 2). OR odds 
ratio; CI confidence interval. P test < 0.05 were considered statisti-
cally significant; p increase < 0.05 were considered statistically sig-
nificant
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caffeic acid, ferulic, and coumaric acids), melanoidins, and 
diterpenes (i.e., cafestol and kahweol), with anti-carcino-
genic properties [74–80]. This might explain why the con-
sumption of less than four coffee cups/day showed a null 
association with BC risk. In addition, experimental research 
on the mechanisms of action of coffee compounds on P53 
suppression showed this effect to be concentration depend-
ent [69, 81–84].
The present study found a four cups/day threshold for 
an increased BC risk in both the overall study population 
and among never smokers. This finding is in line with pre-
vious reported meta-analyses based on case–control stud-
ies, also showing an increased BC risk over four cups/day 
(respectively OR 1.29, 95% CI 1.12–1.48; OR 1.20, 95% CI 
1.12–1.24) [31, 85]. Among smokers, however, a threshold 
of six cups/day was observed; this again shows that the effect 
of coffee on BC risk might be influenced by the faster caf-
feine metabolism among smokers.
An issue that may arise in evaluating the influence of 
coffee consumption on BC risk in hospital-based case–con-
trol studies is that the controls includes patients suffering 
from a disease that may influence coffee intake (i.e., heart 
issues), resulting in inflated ORs. In the present study, there-
fore, stratified analyses by study design (i.e., hospital-based 
controls or population-based controls) were performed, 
and the association with coffee consumption was higher, 
though not significantly, in hospital-based studies than it 
was in population-based studies, where similar results were 
found in both ever versus never coffee consumption and 
dose–response analyses (Supplementary Figs. 1 and 2).
For the present study, the estimates of PAR showed that 
in Europe 7.94% and in North America 4.45% of incidence 
of BC cases could be attributed to heavy coffee consumption 
(i.e., > 4 cups/day). Unfortunately, the exact prevalence of 
heavy coffee drinking in the Eastern Asian population is yet 
unknown. However, since anecdotal evidence suggests that 
coffee consuming is on the rise in Eastern Asia, the PAR is 
expected to increase Eastern Asian countries over the next 
years.
Among the strengths of the BLEND study there is the 
large sample size, allowing to perform detailed analyses 
with enough statistical power to detect smaller effects, the 
study has also some limitations. First, it is known that the 
size of standard coffee cups is varied around the world, and 
the effect of a cup of coffee on BC might, therefore, differ 
between different countries. However, our per-center analy-
ses as well our standardized analysis, in which we trans-
formed a United States (U.S.) cup size to a 237 ml coffee 
cup size according to U.S. Food and Drug Administration 
[51] and an Asian cup size to a 500 ml cup size according to 
the questionnaire used in the study of Lu et al. [45], showed 
similar results (Supplementary Table 3:  ORmodel2 1.25, 95% 
CI 1.06–1.47, p trend = 0.18). Due to large heterogeneity 
among coffee cup size among European countries, Europe 
was not included in these standardized analyses. In addition, 
it is suggested that the strength of coffee brew may compen-
sate for the different serving size between countries [86].
Second, it is often suggested that case–control studies 
are limited in showing causal relation, due to the potential 
recall bias of case–control studies. This might have led to a 
lower reliability of the results compared to those of cohort 
studies. However, although this issue has been addressed 
and analyzed for its consequences in many epidemiologi-
cal/methodological papers [87–90], no clear answer on the 
magnitude of the effect of this specific type of bias could 
be draw.
Thirdly, limited information was available on possible 
risk factors, other than age, gender and smoking, for the 
development of BC, such as body mass index (BMI), physi-
cal activity, socioeconomic status (SES), disinfection by-
products, arsenic in the drinking water, and occupational 
exposures to potentially carcinogenic chemicals. Although, 
adjustments for these factors could have influenced the 
results, current literature shows that only a small proportion 
of BC cases can be attributed to these factors [72]. Last, 
although status as well as duration and intensity of smok-
ing were taken into account in our analysis, the adjustment 
for smoking might still be imperfect due to differences in 
smoking practices (e.g., depth of inhalation or amount of 
inhalation), or differences in types of smoke exposure [67]. 
In addition, since smoking is perceived as a socially unde-
sirable behavior, the use of self-reported questionnaires for 
smoking status, duration, and intensity might have led to 
underreporting of the actual smoking habits.
Conclusion
In summary, the present study, with more than 5,900 cases, 
observed an increased risk between high (> 4 cups/day) cof-
fee consumption and BC among never smokers, while no 
association with BC risk was observed with coffee consump-
tion among smokers. Additionally, it indicates that around 
7.94% of BC cases for Europe and 4.45% of BC cases for 
North America in the population might be attributable to 
heavy coffee consumption (> 4 cups/day).
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